ArticleFuture oncology (London, England)2024

PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.

Fabrice Barlesi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.